Cardiomyopathy in Childhood Cancer Survivors: Lessons from the Past and Challenges for the Future

被引:0
作者
Matthew J. Ehrhardt
Joy M. Fulbright
Saro H. Armenian
机构
[1] St. Jude Children’s Research Hospital,Department of Oncology and Epidemiology and Cancer Control
[2] Children’s Mercy Hospital,Division of Hematology, Oncology and Bone Marrow Transplantation
[3] City of Hope Comprehensive Cancer Center,Department of Population Sciences
来源
Current Oncology Reports | 2016年 / 18卷
关键词
Childhood cancer survivors; Cardiomyopathy; Anthracyclines; Mediastinal radiation; Treatment; Prevention; Risk stratification; Screening;
D O I
暂无
中图分类号
学科分类号
摘要
Childhood cancer survivors are at substantial risk for cancer treatment-related cardiomyopathy. Identification of those at highest risk has presented a longstanding challenge for survivorship researchers. To date, risk stratification approaches to screening and subsequent intervention have largely been driven by demographic and treatment-related exposures, possibly missing an opportunity for a more personalized approach. A growing body of literature suggests associations between cardiomyopathy and a number of genetic and acquired risk factors, supporting a need to incorporate these data into existing surveillance and intervention approaches. Efforts to reduce or eliminate modifiable cardiovascular risk factors are needed; however, the impact of these modifications remains to be seen. Moreover, challenges surrounding identification of effective cardiomyopathy treatment strategies in cancer survivors are ongoing. Despite these uncertainties, more accurate identification of those at highest risk and implementation of early and effective interventions for those with disease will lead to improved outcomes for childhood cancer survivors.
引用
收藏
相关论文
共 175 条
[1]  
Robison LL(2014)Survivors of childhood and adolescent cancer: life-long risks and responsibilities Nat Rev Cancer 14 61-70
[2]  
Hudson MM(2006)Chronic health conditions in adult survivors of childhood cancer N Engl J Med 355 1572-82
[3]  
Oeffinger KC(2013)Clinical ascertainment of health outcomes among adults treated for childhood cancer JAMA 309 2371-81
[4]  
Mertens AC(2009)Late mortality among 5-year survivors of childhood cancer: a summary from the Childhood Cancer Survivor Study J Clin Oncol 27 2328-38
[5]  
Sklar CA(2008)Long-term cardiac and pulmonary complications of cancer therapy Hematol Oncol Clin N Am 22 305-18
[6]  
Hudson MM(2001)Decreasing late mortality among five-year survivors of cancer in childhood and adolescence: a population-based study in the Nordic countries J Clin Oncol 19 3173-81
[7]  
Ness KK(2001)Late mortality experience in five-year survivors of childhood and adolescent cancer: the Childhood Cancer Survivor Study J Clin Oncol 19 3163-72
[8]  
Gurney JG(2005)Risk of morbidity and mortality from cardiovascular disease following radiotherapy for childhood cancer: a systematic review Cancer Treat Rev 31 173-85
[9]  
Armstrong GT(2005)Pathophysiology of anthracycline- and radiation-associated cardiomyopathies: implications for screening and prevention Pediatr Blood Cancer 44 600-6
[10]  
Liu Q(1995)Female sex and drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer N Engl J Med 332 1738-43